NO2625199T3 - - Google Patents

Info

Publication number
NO2625199T3
NO2625199T3 NO11764764A NO11764764A NO2625199T3 NO 2625199 T3 NO2625199 T3 NO 2625199T3 NO 11764764 A NO11764764 A NO 11764764A NO 11764764 A NO11764764 A NO 11764764A NO 2625199 T3 NO2625199 T3 NO 2625199T3
Authority
NO
Norway
Application number
NO11764764A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2625199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2625199T3 publication Critical patent/NO2625199T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO11764764A 2010-10-08 2011-10-07 NO2625199T3 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Publications (1)

Publication Number Publication Date
NO2625199T3 true NO2625199T3 (https=) 2018-04-21

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11764764A NO2625199T3 (https=) 2010-10-08 2011-10-07

Country Status (28)

Country Link
US (9) US9717791B2 (https=)
EP (5) EP3299390A1 (https=)
JP (2) JP5537740B2 (https=)
KR (3) KR20130110179A (https=)
CN (2) CN103154031A (https=)
AU (1) AU2011311482B2 (https=)
BR (1) BR112013008501A2 (https=)
CA (1) CA2813900C (https=)
CL (1) CL2013000930A1 (https=)
CY (1) CY1119942T1 (https=)
DK (1) DK2625199T3 (https=)
ES (1) ES2660770T3 (https=)
HK (1) HK1247932A1 (https=)
HR (1) HRP20180301T1 (https=)
HU (1) HUE038334T2 (https=)
IL (1) IL225310A (https=)
LT (1) LT2625199T (https=)
MA (1) MA34646B1 (https=)
MX (1) MX356279B (https=)
NO (1) NO2625199T3 (https=)
PH (1) PH12013500660B1 (https=)
PL (1) PL2625199T3 (https=)
PT (1) PT2625199T (https=)
RU (2) RU2665954C1 (https=)
SG (1) SG188979A1 (https=)
SI (1) SI2625199T1 (https=)
TW (2) TWI564022B (https=)
WO (1) WO2012045848A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
CN103154031A (zh) 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2783014A1 (en) * 2011-11-21 2014-10-01 Novartis AG Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
SG11201507482UA (en) * 2013-03-15 2015-10-29 Amgen Inc Methods for treating psoriasis using an anti-il-23 antibody
SG11201507483PA (en) * 2013-03-15 2015-10-29 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
US11421025B2 (en) 2013-12-27 2022-08-23 Osaka University Treatment of IL-17A diseases
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
CA2944605C (en) * 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
US10220076B2 (en) 2014-05-15 2019-03-05 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
JP6663910B2 (ja) * 2014-08-26 2020-03-13 アムジェン ケー・エー，インコーポレイテッド 抗ＴＮＦ−α抗体療法を受けた乾癬患者を治療するための方法
CN115957326A (zh) * 2014-09-10 2023-04-14 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3265493B1 (en) 2015-03-02 2024-01-10 180 Therapeutics LP Method of treating a localized fibrotic disorder using an il-33 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
CN116059350A (zh) * 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
WO2018015880A1 (en) * 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2019505516A (ja) * 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
CN111032691A (zh) * 2017-08-23 2020-04-17 伊莱利利公司 生殖器银屑病的治疗
TWI725532B (zh) * 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
TW202126329A (zh) 2019-09-20 2021-07-16 瑞士商諾華公司 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
WO2022184114A1 (zh) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250442A (en) 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
JP4159682B2 (ja) 1998-12-22 2008-10-01 株式会社クラレ 止血材
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US8039642B2 (en) 2003-12-09 2011-10-18 Life Technologies Corporation Pyrenyloxysulfonic acid fluorescent agents
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
ES2569409T3 (es) 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
US20080199460A1 (en) * 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1963368B3 (en) 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
BRPI0706788A2 (pt) 2006-01-31 2011-04-05 Novartis Ag anticorpos antagonistas il-17
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
CA2662350A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
EP2152318A4 (en) * 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
US20100239590A1 (en) 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7720605B2 (en) 2007-06-22 2010-05-18 Weyerhaeuser Nr Company Identifying vegetation attributes from LiDAR data
RU2341272C1 (ru) 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
US20090301682A1 (en) 2008-06-05 2009-12-10 Baker Hughes Incorporated Casting furnace method and apparatus
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
NZ591484A (en) 2008-09-29 2012-09-28 Roche Glycart Ag Antibodies against human il 17 and uses thereof
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
WO2010065491A2 (en) 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
TWI541021B (zh) 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
CN103154031A (zh) 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
EP2783014A1 (en) 2011-11-21 2014-10-01 Novartis AG Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
WO2013158821A2 (en) 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA3002622A1 (en) 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
US11280479B2 (en) 2017-10-18 2022-03-22 The Sloan Company Sign box light module

Also Published As

Publication number Publication date
PH12013500660B1 (en) 2017-10-27
US20250161445A1 (en) 2025-05-22
IL225310A (en) 2016-10-31
KR20150018595A (ko) 2015-02-23
BR112013008501A2 (pt) 2016-08-16
SI2625199T1 (en) 2018-03-30
MA34646B1 (fr) 2013-11-02
US11534490B2 (en) 2022-12-27
EP2625199A1 (en) 2013-08-14
HUE038334T2 (hu) 2018-10-29
CL2013000930A1 (es) 2014-03-28
SG188979A1 (en) 2013-05-31
CA2813900A1 (en) 2012-04-12
EP2625199B1 (en) 2017-11-22
TWI564022B (zh) 2017-01-01
US10583190B2 (en) 2020-03-10
IL225310A0 (en) 2013-06-27
HRP20180301T1 (hr) 2018-03-23
US20210113688A1 (en) 2021-04-22
KR101620771B1 (ko) 2016-05-12
EP4137514A1 (en) 2023-02-22
PH12013500660A1 (en) 2013-05-20
US20170304439A1 (en) 2017-10-26
US9717791B2 (en) 2017-08-01
MX356279B (es) 2018-05-22
TWI548419B (zh) 2016-09-11
US20130202610A1 (en) 2013-08-08
US12594331B2 (en) 2026-04-07
ES2660770T3 (es) 2018-03-26
JP2014114288A (ja) 2014-06-26
EP3299390A1 (en) 2018-03-28
CN103154031A (zh) 2013-06-12
EP4670788A3 (en) 2026-03-18
CN107029234A (zh) 2017-08-11
US12551554B2 (en) 2026-02-17
RU2591083C2 (ru) 2016-07-10
RU2665954C1 (ru) 2018-09-05
KR20130110179A (ko) 2013-10-08
TW201630625A (zh) 2016-09-01
DK2625199T3 (en) 2018-02-26
RU2013120957A (ru) 2014-11-20
JP2013543501A (ja) 2013-12-05
HK1247932A1 (en) 2018-10-05
PT2625199T (pt) 2018-02-28
US12594332B2 (en) 2026-04-07
LT2625199T (lt) 2018-03-12
PL2625199T3 (pl) 2018-04-30
EP3792281A1 (en) 2021-03-17
CA2813900C (en) 2017-01-10
US20230321231A1 (en) 2023-10-12
US20200171147A1 (en) 2020-06-04
EP4670788A2 (en) 2025-12-31
AU2011311482A1 (en) 2013-04-04
CY1119942T1 (el) 2018-12-12
US20210162044A1 (en) 2021-06-03
TW201216984A (en) 2012-05-01
WO2012045848A1 (en) 2012-04-12
US20250161444A1 (en) 2025-05-22
JP5537740B2 (ja) 2014-07-02
AU2011311482B2 (en) 2014-05-29
US20250161443A1 (en) 2025-05-22
KR20140097566A (ko) 2014-08-06
MX2013003916A (es) 2013-06-03

Similar Documents

Publication Publication Date Title
BR112013008959A2 (https=)
BR112012030039A2 (https=)
BR112012028408A2 (https=)
BR112012029986A2 (https=)
BR112012027808A2 (https=)
BR112012026492A2 (https=)
BR112012031500A2 (https=)
BR112012026946A2 (https=)
BR112012025482A2 (https=)
BR112013006400A2 (https=)
BR112012031826A2 (https=)
BR112012025577A2 (https=)
NO2625199T3 (https=)
BR112012028186A2 (https=)
BR112012027015A2 (https=)
BR112012027945A2 (https=)
BR112013010949A2 (https=)
BR112012026403A2 (https=)
BR112013003284A2 (https=)
BR112013002646A2 (https=)
BR112013006825A2 (https=)
BR112012028859A2 (https=)
BR112013007728A2 (https=)
BR112012030078A2 (https=)
BR112013007731A2 (https=)